	US 12,329,761 B2
	Methods of using rho kinase inhibitors to treat alzheimer's disease
Thomas MacAllister, Arlington, VA (US); and Sven Jacobson, New York, NY (US)
Assigned to Woolsey Pharmaceuticals, Inc., St. Petersburg, FL (US)
Appl. No. 17/996,812
Filed by Woolsey Pharmaceuticals, Inc., St. Petersburg, FL (US)
PCT Filed Jan. 8, 2021, PCT No. PCT/US2021/012588 § 371(c)(1), (2) Date Oct. 21, 2022, PCT Pub. No. WO2021/216139, PCT Pub. Date Oct. 28, 2021.
Claims priority of provisional application 63/014,272, filed on Apr. 23, 2020.
Prior Publication US 2023/0190765 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5513 (2006.01); A61P 25/28 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/5513 (2013.01) [A61P 25/28 (2018.01); A61K 9/0053 (2013.01)]

12 Claims

1. A method of improving cognition in a patient with Alzheimer's Disease comprising orally administering to a patient suffering from Alzheimer's Disease a pharmacologically effective amount of fasudil or a pharmacologically acceptable salt thereof, wherein the fasudil or a pharmacologically acceptable salt thereof is administered in a dose of between 70 and 140 mg per day in an immediate release formulation.